lunes, 30 de julio de 2018

Philips and Oxford University Hospitals NHS Foundation Trust join hands to set up digital pathology network

Philips and Oxford University Hospitals NHS Foundation Trust join hands to set up digital pathology network

News-Medical



Philips and Oxford University Hospitals NHS Foundation Trust join hands to set up digital pathology network

Oxford University Hospitals NHS Foundation Trust creates advanced diagnostic network to help improve patient care across Wiltshire, Buckinghamshire and Oxfordshire
Royal Philips, a global leader in health technology, and Oxford University Hospitals (OUH) NHS Foundation Trust, today announced plans to create a digital pathology network to help drive faster and more efficient diagnoses for patients. OUH will deploy the Philips IntelliSite Pathology Solution at the John Radcliffe Hospital in Oxford, which will serve as a central laboratory service for partner sites at Milton Keynes University Hospital NHS Foundation Trust and Great Western Hospital NHS Foundation Trust in Swindon.
Pathologists play a critical role in disease detection, particularly with cancer diagnosis. Traditionally, pathologists analyse tissue samples on glass slides under a microscope. When seeking a consultation with a sub-specialist, these glass slides must be transported to the second site, which can result in lost or damaged slides or delays in diagnosis. By creating a digital network, OUHwill leverage the Philips IntelliSite Pathology Solution, including its Ultra Fast Scanner and Image Management System, to allow clinicians across the three regions and within the Thames Valley Cancer Network to collaborate remotely on patient cases. This enhanced collaboration will help reduce delays in slide transport times, encourage more efficient workflows across the sites, and enable quicker access to specialist pathology opinions. Digital pathology will also support NHS Improvement’s proposed Pathology networks, bringing together clinical expertise with the goal of enhancing patient outcomes.

Digital pathology will transform microscopy

“As an NHS Global Digital Exemplar committed to improving patient care by embracing the latest digital technologies and cross-site collaborations, this partnership aims to modernize patient care and offer innovative world-leading services,” said ProfessorClare Verrill, Honorary Consultant in Cellular Pathology, Oxford University Hospitals. “Initially starting with some specialist areas, we hope to soon make our pathology services fully digital, meaning our laboratory teams can maximize efficiency and  focus on analyzing samples rather than spending time manually transporting slides between hospitals.”
“With 70% of NHS diagnoses requiring a pathology sample, and with sample analysis becoming increasingly sophisticated while demand increases, Philips is committed to collaborating to modernize UK pathology services,” said Marlon Thompson, General Manager of Philips Digital Pathology Solutions. “Philips wants to help providers meet growing demand by moving pathology from the era of microscopes and fragile stacks of sample slides to one of clinical efficacy with sample images uploaded quickly and analyzed robustly within the Philips IntelliSite Pathology Solution. I believe this agreement creates the first digital pathology network with scanning capabilities at multiple sites within the NHS in England, which is a great achievement and a very positive prospect for patients and clinicians alike.”
Philips IntelliSite Pathology Solution is an automated digital pathology image creation, viewing and management system comprised of an ultra-fast scanner and image management system. This solution contains advanced software tools to manage the scanning, storage, presentation, reviewing, and sharing of images. Philips IntelliSite Pathology Solution is available in various countries globally for primary diagnostic use. In addition to its CE-IVD clearance in Europe, it was the first – and currently only – digital pathology solution allowed to be marketed for primary diagnostic use in the U.S. since April 2017 and in Japan since December 2017.
Clinical cases will commence once network installation has completed, expected in Q3 2018.

No hay comentarios: